Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Francois Guérard"'
Autor:
Maarten Vanermen, Mathilde Ligeour, Maria-Cristina Oliveira, Jean-François Gestin, Filipe Elvas, Laurent Navarro, François Guérard
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-57 (2024)
Abstract Background 211At-radiopharmaceuticals are currently the subject of growing studies for targeted alpha therapy of cancers, which leads to the widening of the scope of the targeting vectors, from small molecules to peptides and proteins. This
Externí odkaz:
https://doaj.org/article/16bd85d03400448886c43452b4e5a9fc
Publikováno v:
Nuclear Medicine and Biology. :S43-S44
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22906a3da1d0e169a4bf964d16fee4d2
https://doi.org/10.1016/s0969-8051(22)00124-x
https://doi.org/10.1016/s0969-8051(22)00124-x
Autor:
Loris Roncali, Séverine Marionneau-Lambot, Charlotte Roy, Romain Eychenne, Sébastien Gouard, Sylvie Avril, Nicolas Chouin, Jérémie Riou, Mathilde Allard, Audrey Rousseau, François Guérard, François Hindré, Michel Chérel, Emmanuel Garcion
Publikováno v:
EBioMedicine, Vol 105, Iss , Pp 105202- (2024)
Summary: Background: Glioblastoma (GB), the most aggressive brain cancer, remains a critical clinical challenge due to its resistance to conventional treatments. Here, we introduce a locoregional targeted-α-therapy (TAT) with the rat monoclonal anti
Externí odkaz:
https://doaj.org/article/c893b207ab6f4738b36ea397dd0319b1
Autor:
Justine Perrin, Marisa Capitao, Marie Mougin-Degraef, François Guérard, Alain Faivre-Chauvet, Latifa Rbah-Vidal, Joëlle Gaschet, Yannick Guilloux, Françoise Kraeber-Bodéré, Michel Chérel, Jacques Barbet
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
The impressive development of cancer immunotherapy in the last few years originates from a more precise understanding of control mechanisms in the immune system leading to the discovery of new targets and new therapeutic tools. Since different stages
Externí odkaz:
https://doaj.org/article/917a62510146415d8739dae10daa49e9
Publikováno v:
Pharmaceutics, Vol 13, Iss 6, p 906 (2021)
Among all existing radionuclides, only a few are of interest for therapeutic applications and more specifically for targeted alpha therapy (TAT). From this selection, actinium-225, astatine-211, bismuth-212, bismuth-213, lead-212, radium-223, terbium
Externí odkaz:
https://doaj.org/article/71e01208e20a4ebd8aa898559bef0639